Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 9/20 | 0.50 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.44 |
| ▸ | FCER2 | P06734 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390652 | 0.96 | MME (0.49) | GNRHRGPR132MMEACECPA1 | |
| SCHEMBL30038541 | 0.94 | GNRHR (0.50) | GNRHRGPR132MMEACECPA1 | |
| SCHEMBL29374168 | 0.92 | GNRHR (0.49) | GNRHRGPR132ABCB11FCER2DRD1 | |
| SCHEMBL30509011 | 0.92 | GPR132 (0.50) | GNRHRGPR132MMEOPRD1KISS1R | |
| SCHEMBL19620196 | 0.91 | GPR132 (0.47) | GNRHRGPR132MMEACECPA1 | |
| SCHEMBL29631784 | 0.88 | KISS1R (0.46) | GNRHRMMEACECPA1ACE2 | |
| SCHEMBL15344724 | 0.88 | GPR132 (0.53) | GNRHRGPR132MMEACECPA1 | |
| SCHEMBL30552202 | 0.87 | KISS1R (0.47) | GNRHRMMEACECPA1ACE2 | |
| SCHEMBL31215087 | 0.87 | MME (0.57) | MMEACECPA1ACE2OPRD1 | |
| SCHEMBL31215105 | 0.87 | MME (0.57) | MMEACECPA1ACE2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177521-A1 | PROCESS FOR THE PREPARATION OF DEGARELIX | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-06-09 | — | — | US | claimed |
| WO-2025264177-A1 | METHOD FOR CLEAVING PROTECTING GROUPS AND ORGANIC COMPOUNDS FROM SUPPORTS | POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) | 2025-12-26 | — | — | WO | disclosed |
| US-20220177521-A1 | PROCESS FOR THE PREPARATION OF DEGARELIX | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177521-A1 | PROCESS FOR THE PREPARATION OF DEGARELIX | VIP, PEPD, SSTR4 | GNRHR 42/4885GPR132 2216/4885MME 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.